Search research articles
Contact Us
Filters
Showing results (791-800 of 811) with videos related to
Page
of 82
Sort By:
Journal for Immunotherapy of Cancer
|
May 23, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma
Sofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, et al.
Science Immunology
|
July 7, 2023
Restoring tumor immunogenicity with dendritic cell reprogramming
Olga Zimmermannova, Alexandra G Ferreira, Ervin Ascic, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Cell Reports. Medicine
|
March 19, 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
Tine J Monberg, Santeri A Pakola, Benedetta Albieri, et al.
Cell Reports
|
November 9, 2017
Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
Nicolai J Wewer Albrechtsen, Rune E Kuhre, Daniel Hornburg, et al.
The British Journal of Surgery
|
June 6, 2025
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial
Liselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
Cell
|
July 25, 2023
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy
Garry Dolton, Cristina Rius, Aaron Wall, et al.
Journal of Medical Screening
|
May 7, 2020
Early detection of breast cancer rectifies inequality of breast cancer outcomes
László Tabár, Tony Hsiu-Hsi Chen, Amy Ming-Fang Yen, et al.
Page
of 82
Search research articles
Search
Showing results (791-800 of 811) with videos related to
Sort By:
Page
of 82
Journal for Immunotherapy of Cancer
|
May 23, 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma
Sofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, et al.
Science Immunology
|
July 7, 2023
Restoring tumor immunogenicity with dendritic cell reprogramming
Olga Zimmermannova, Alexandra G Ferreira, Ervin Ascic, et al.
The Lancet. Oncology
|
March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, et al.
Cell Reports. Medicine
|
March 19, 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
Tine J Monberg, Santeri A Pakola, Benedetta Albieri, et al.
Cell Reports
|
November 9, 2017
Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
Nicolai J Wewer Albrechtsen, Rune E Kuhre, Daniel Hornburg, et al.
The British Journal of Surgery
|
June 6, 2025
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial
Liselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
Cell
|
July 25, 2023
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy
Garry Dolton, Cristina Rius, Aaron Wall, et al.
Journal of Medical Screening
|
May 7, 2020
Early detection of breast cancer rectifies inequality of breast cancer outcomes
László Tabár, Tony Hsiu-Hsi Chen, Amy Ming-Fang Yen, et al.
Page
of 82